Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Noribogaine dose escalation in healthy volunteers
NCT06480981Phase 1Completed
- Sponsor
- DemeRx
- Start
- Jun 2024
- Primary completion
- Dec 2024
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of noribogaine (4 arms), sponsored by DemeRx. Primary endpoints: Maximum Plasma Concentration at Day 8, Time to Maximum Plasma Concentration at Day 8 and 3 more. Started Jun 2024; status: completed.
02
Drugs
noribogaine
Beyond the preview
Go deeper on NCT06480981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06480981.